Honey Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 87.16%
- Profit Growth 1726.71%
- Ebitda 1885.46%
- Net Worth 254.12%
- Total Assets 949.56%
About Honey Drugs And Pharmaceuticals
Honey Drugs And Pharmaceuticals Private Limited (HDAPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 September 2015 (Nine years and four months 9 days old ). Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Satish Poola and Dilli Nallakukkala serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909TN2015PTC102391
-
Company No.
102391
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Sep 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Honey Drugs And Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Poola
|
Director | 30-Sep-2015 | Current |
|
Dilli Nallakukkala
|
Director | 13-Jul-2023 | Current |
Financial Performance of Honey Drugs And Pharmaceuticals.
Honey Drugs And Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 87.16% increase. The company also saw a substantial improvement in profitability, with a 1726.71% increase in profit. The company's net worth Soared by an impressive increase of 254.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Honey Drugs And Pharmaceuticals?
In 2019, Honey Drugs And Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Honey Drugs And Pharmaceuticals?
Unlock and access historical data on people associated with Honey Drugs And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Honey Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Honey Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
